[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-380430-105":59,"doc-detail-380430-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","neoadjuvant-sintilimab-combined-with-chemotherapy-in-resectable-locally-advanced-non-small-cell-lung-cancer-case-series-and-literature-review","Neoadjuvant sintilimab combined with chemotherapy in resectable locally advanced non-small cell lung cancer - case series and literature review","","Neoadjuvant immunotherapy combined with chemotherapy is increasingly promising for locally advanced non-small cell lung cancer, yet real-world evidence remains limited. This retrospective study evaluates the safety and effectiveness of sintilimab, a PD-1 inhibitor, administered with platinum-based chemotherapy as neoadjuvant therapy in patients with potentially resectable stage II–III disease. Patients received planned cycles followed by radical resection, with pathologic complete response as the primary endpoint. Secondary outcomes included objective response rate and treatment safety.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/neoadjuvant-sintilimab-combined-with-chemotherapy-in-resectable-locally-advanced-non-small-cell-lung-cancer-case-series-and-literature-review/380430/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/neoadjuvant-sintilimab-combined-with-chemotherapy-in-resectable-locally-advanced-non-small-cell-lung-cancer-case-series-and-literature-review/380430.png","ImageObject",300,407,{"name":92,"@type":93},"Đào","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-24",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the study’s main objective?","Question",{"text":112,"@type":113},"To assess the safety and effectiveness of sintilimab combined with chemotherapy as a neoadjuvant treatment modality for potentially resectable non-small cell lung cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were treatments scheduled before surgery?",{"text":117,"@type":113},"Patients received sintilimab intravenously (200 mg, every 3 weeks) plus platinum-based chemotherapy every 3 weeks for 2 to 4 cycles, with radical lung cancer resection planned about 4–11 weeks after the last dose.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the primary and secondary endpoints?",{"text":121,"@type":113},"The primary endpoint was pathologic complete response (pCR). Secondary endpoints were objective response rate (ORR) and safety.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},380430,1790615359,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144},1374402968488,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Yin et al. World Journal of Surgical Oncology (2023) 21:304  \n[https://doi.org/10.1186/s12957-023-03194-4](https://doi.org/10.1186/s12957-023-03194-4)  \nWorld Journal of Surgical Oncology  \n REVIEW Open Access  \nNeoadjuvant sintilimab combined  \nwith chemotherapy in resectable locally advanced non-small cell lung cancer: case series and literature review  \nCunli Yin1†, Bin Hu2†, Xi Yang3, Lingna Kou4, BoTian2, Chenghao Wang2, Siru Li 1, Bin Liu4 and Jun Ge4*  \nAbstract  \nBackground In recent years, neoadjuvant immunotherapy with chemotherapy has shown increasing promise for locally advanced non-small cell lung cancer (NSCLC) . However, to establish its clinical efficacy and safety, it is imperative to amass more real-world clinical data. This retrospective study aims to assess the safety and effectiveness of combing sintilimab, a PD-1 inhibitor, with chemotherapy as a neoadjuvant treatment modality in patients diagnosed with potentially resectable NSCLC.  \nMethods We retrospectively reviewed patients with stage II-III NSCLC receiving neoadjuvant chemoimmunotherapy in Sichuan Cancer Hospital between February 2021 and February 2023. Sintilimab injection (intravenously,200 mg, iv, d1, q3w) and platinum-based chemotherapy were administered intravenously every 3 weeks, with radical lung cancer resection planned approximately 4–11 weeks after the last dose. The primary endpoint of the study was pathologic complete response (pCR) . The secondary endpoints were objective response rate (ORR), and safety.  \nResult Thirteen patients were enrolled, they were mostly diagnosed with stage III NSCLC (IIB 15.4% IIIA 38 . 5%; IIIB 46. 2%) . Most of them had pathologically confirmed squamous cell carcinoma (69 . 2%) .  \nAll patients received sintilimab combined with platinum-based chemotherapy for 2 to 4 cycles. Notably, none of the patients necessitated a reduction in initial dosages or treatment postponement due to intolerable adverse events. Then, all of them underwent surgical operation. Impressively, nine patients (69 . 2%) achieved a pathologic complete response. The objective response rate (ORR) stood at 46 . 15% . Nine patients experienced neoadjuvant treatment-related adverse events (TRAEs), with only one patient (7 . 6%) encountering a grade 4 neoadjuvantTRAE. Conclusion Therefore, the current study suggested that neoadjuvant sintilimab plus platinum-based chemotherapy can be a safe approach in increasing the efficiency of treatment and hopefully improving the prognosis of patients with potentially resectable locally advanced NSCLC.  \nKeywords Non-small cell lung carcinoma, Neoadjuvant, Chemoimmunotherapy, PD-1(programmed cell death protein 1), Sintilimab  \n†CunliYin and Bin Hu contributed equally to this work and should be regarded as co-first authors.  \n*Correspondence: Jun Ge [gejun0228@163.com](gejun0228@163.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2023. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ()[. The Creative Commons Public Domain Dedication waiver (](http://creativecommons.org/licen","cbCaif6vjDxycLWs","https://ap.wps.com/l/cbCaif6vjDxycLWs","pdf",1378808,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Introduction\n## Background and rationale","[{\"question\":\"What is the study’s main objective?\",\"answer\":\"To assess the safety and effectiveness of sintilimab combined with chemotherapy as a neoadjuvant treatment modality for potentially resectable non-small cell lung cancer.\"},{\"question\":\"How were treatments scheduled before surgery?\",\"answer\":\"Patients received sintilimab intravenously (200 mg, every 3 weeks) plus platinum-based chemotherapy every 3 weeks for 2 to 4 cycles, with radical lung cancer resection planned about 4–11 weeks after the last dose.\"},{\"question\":\"What were the primary and secondary endpoints?\",\"answer\":\"The primary endpoint was pathologic complete response (pCR). Secondary endpoints were objective response rate (ORR) and safety.\"}]","Neoadjuvant sintilimab combined with chemotherapy in resectable locally advanced non-small cell lung cancer - case series and literature review | PDF",1790240152,23]